Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study
| Autor: | Zainulabedin M. Saiyed, Nancy E Lane, James P. Lugo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Aging Placebo-controlled study Medicine (miscellaneous) Osteoarthritis Knee function Cartilage Oligomeric Matrix Protein Body Mass Index 0302 clinical medicine Medicine Pain Measurement Nutrition And Dietetics Nutrition and Dietetics Pain Research Undenatured type II collagen Osteoarthritis Knee Middle Aged C-Reactive Protein Treatment Outcome Tolerability 6.1 Pharmaceuticals Female Matrix Metalloproteinase 3 Chronic Pain Adult medicine.medical_specialty WOMAC Visual analogue scale Clinical Trials and Supportive Activities Placebo Clinical trials on glucosamine and chondroitin 03 medical and health sciences Complementary and Alternative Medicine Double-Blind Method Clinical Research Internal medicine Complementary and Integrative Health Humans Knee T regulatory cell Collagen Type II Nutrition Aged 030203 arthritis & rheumatology Nutrition & Dietetics business.industry Interleukin-6 Research Arthritis Body Weight Repeated measures design Evaluation of treatments and therapeutic interventions medicine.disease Surgery 030104 developmental biology Musculoskeletal Dietary Supplements business Biomarkers |
| Zdroj: | Lugo, JP; Saiyed, ZM; & Lane, NE. (2016). Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study. Nutrition Journal, 15(1), 14. doi: 10.1186/s12937-016-0130-8. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bf9f64v Nutrition journal, vol 15, iss 1 Nutrition Journal |
| DOI: | 10.1186/s12937-016-0130-8. |
| Popis: | Undenatured type II collagen (UC-II) is a nutritional supplement derived from chicken sternum cartilage. The purpose of this study was to evaluate the efficacy and tolerability of UC-II for knee osteoarthritis (OA) pain and associated symptoms compared to placebo and to glucosamine hydrochloride plus chondroitin sulfate (GC). One hundred ninety one volunteers were randomized into three groups receiving a daily dose of UC-II (40 mg), GC (1500 mg G & 1200 mg C), or placebo for a 180-day period. The primary endpoint was the change in total Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) from baseline through day 180 for the UC-II group versus placebo and GC. Secondary endpoints included the Lequesne Functional Index (LFI), the Visual Analog Scale (VAS) for pain and the WOMAC subscales. Modified intent-to-treat analysis were performed for all endpoints using analysis of covariance and mixed model repeated measures, while incremental area under the curve was calculated by the intent-to-treat method. At day 180, the UC-II group demonstrated a significant reduction in overall WOMAC score compared to placebo (p = 0.002) and GC (p = 0.04). Supplementation with UC-II also resulted in significant changes for all three WOMAC subscales: pain (p = 0.0003 vs. placebo; p = 0.016 vs. GC); stiffness (p = 0.004 vs. placebo; p = 0.044 vs. GC); physical function (p = 0.007 vs. placebo). Safety outcomes did not differ among the groups. UC-II improved knee joint symptoms in knee OA subjects and was well-tolerated. Additional studies that elucidate the mechanism for this supplement’s actions are warranted. CTRI/2013/05/003663 ; CTRI/2013/02/003348 . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|